Price
CHART BY
Frequently asked questions
What is Insulet's market capitalization?
The market capitalization of Insulet is $9.15B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Insulet's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Insulet is 26.16. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Insulet?
Insulet's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $5.044. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Insulet's stock?
Currently, 28 analysts cover Insulet's stock, with a consensus target price of $169.86. Analyst ratings provide insights into the stock's expected performance.
What is Insulet's revenue over the trailing twelve months?
Over the trailing twelve months, Insulet reported a revenue of $3.05B.
What is the EBITDA for Insulet?
Insulet's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $639.60M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Insulet?
Insulet has a free cash flow of $293.80M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Insulet have, and what sector and industry does it belong to?
Insulet employs approximately 5,400 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Insulet's shares?
The free float of Insulet is 69.06M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $9.15B
- EPS (TTM)
- $5.044
- Free Float
- 69.06M
- P/E ratio (TTM)
- 26.16
- Revenue (TTM)
- $3.05B
- EBITDA (TTM)
- $639.60M
- Free Cashflow (TTM)
- $293.80M
Pricing
- 1D span
- $131.23$136.05
- 52W span
- $126.50$354.87
Analyst Ratings
The price target is $169.86 and the stock is covered by 28 analysts.
Buy
16
Hold
12
Sell
0
Information
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
- Employees
- 5,400
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- Primary Ticker
- PODD
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet